Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00560716 · ClinicalTrials.gov registry record · Phase 1
A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors
A Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 25
- Enrollment target
NCT00560716: Clinical Trial Phase 1 study, sponsored by Cyclacel Pharmaceuticals.
NCT00560716 is a Phase 1 study that was terminated before completion, run by Cyclacel Pharmaceuticals. The registered enrollment target is 25 participants, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00560716, a Phase 1 study, was terminated before completion, sponsored by Cyclacel Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 25 participants
- Enrollment target
Study Summary
This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.
Primary Outcome
Safety and tolerability; SAEs and AEs
Interventions
- DRUG CYC116
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 25 participants |
| Start Date | 2007-06 |
| Est. Completion | 2009-11 |
| Phase | Phase 1 |
Why NCT00560716 stopped before completion
NCT00560716 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 25 participants, a relatively small participant target, below the 60-participant average among 29,502 other Phase 1 trials with a reported enrollment target (58% lower).
The record links to 0 conditions, and to 1 intervention - of which CYC116 is the first listed.
NCT00560716 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00560716 about?
NCT00560716 is a clinical study titled "A Phase I Pharmacologic Study of CYC116, an Oral Aurora Kinase Inhibitor, in Patients With Advanced Solid Tumors". This is a phase I study of an investigational cancer drug, CYC116, in patients with advanced solid tumors.
What is the current status of trial NCT00560716?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 25 participants. The study started on 2007-06. Estimated completion is 2009-11.
What interventions are being tested in trial NCT00560716?
The interventions under investigation include: CYC116 (DRUG).
Who is sponsoring clinical trial NCT00560716?
This trial is sponsored by Cyclacel Pharmaceuticals, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00560716's enrollment target sits among peer trials
25 1495th of 2000 higher than 481 of 2,000 other Phase 1 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 1 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01166854 · 25 participants
Characterization of Familial Myopathy and Paget Disease of Bone
- NCT01913106 · 25 participants · Phase 1
HSV-tk + Valacyclovir Therapy in Combination With Brachytherapy for Recurrent Prostate Cancer
- NCT02138669 · 25 participants · NA
Intacs Prescription Inserts for Keratoconus Patients
- NCT02174549 · 25 participants · Phase 1
Dose-defining Study of Tirapazamine Combined With Embolization in Liver Cancer
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia